
ALK's archrival, Stallergenes Greer, is closing in on the lucrative allergy pill market, which ALK has called one of the most important future growth markets.
On Monday, Stallergenes revealed in a press release that it has obtained European approval for its dust mite allergy tablet Stagr320.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app